ReleaseWire Connect

The global Chronic Heart Failure (CHF) therapeutics market, valued at $3,171.3m in 2006, grew at a Compound Annual Growth Rate (CAGR) of 4.0% to $3,849.9m in 2011. GlobalData’s analysis suggests that the global CHF therapeutics market will grow at a CAGR of 3.1% during the forecast period to $4,918.4m by 2019. This growth will be primarily due to the expected launch of LCZ696 in 2015. The treatment-seeking population is expected to grow due to increased life expectancy and awareness of health among patients, as well as growth in the aging population more susceptible to Acute Heart Failure (AHF). Competition in the CHF therapeutics market is weak, as it is dominated by generic drugs such as beta-blockers (metropolol), diuretics (furosemide, spironolactone), digoxin, carvedilol and ramipril. Diovan (valsartan) is the only branded product, but it is expected to lose its patent protection in 2012 in the US.

The global Floating Production Storage and Offloading (FPSO) market is dominated by the Middle East and Africa, accounting for nearly a third of the global FPSO-based crude oil and natural gas production capacity of 5,197.01 million barrels of oil equivalent (MMboe) in 2011. South and Central America and Asia-Pacific contribute 27.3% and 21.8%, respectively, to the global FPSO-based production capacity.

Global bioethanol production started in 2003 with 33,514 million liters and grew to 105,608 million liters by 2011 at a CAGR of 15.4%. This was primarily due to government support in the form of subsidies. The blending targets and excise tax credit schemes has encouraged the growth of global bioethanol market National targets in Canada has helped to grow the bioethanol market whereas the blending targets has helped the growth of Chinese bioethanol market. The global production is forecast to grow at a Compound Annual Growth Rate (CAGR) of 4.4% during 2011-2020, reaching 154,962 million liters in 2020.

The global wound closure devices market was valued at $3.3 billion in 2011 and is forecast to grow at a Compound Annual Growth Rate (CAGR) of 4.9% to reach $4.6 billion in 2018. The market is expected to be driven by the significant increase in the number of surgeries, especially cosmetic, cardiovascular, orthopedic and laparoscopic surgeries, increase in the number of sports injuries, increase in the global elderly population and large number of road accidents in the emerging countries.